Nuvation Bio Inc NUVB

US Pharmaceuticals

$6.33 ▼ -5.52% ($-0.37)

⬇️ Below Yest. Low 🔥 High Short Interest 📅 Earnings This Week

Open $6.68

Prev Close $6.70

Day Range $6.30 – $6.69

52W Range $2.18 – $9.75

Market Cap $2.21B

Beta 1.52

EPS (TTM) $-0.43

📋 Company Profile

Industry	Pharmaceuticals
Country	US
Exchange	NEW YORK STOCK EXCHANGE, INC.
Currency	USD
IPO Date	2020-07-01
Shares Out.	348,200,000
Website	nuvationbio.com/ ↗
Phone	13322086102
Employees	307
Revenue	$83.2M
Gross Profit	$77.6M
Net Income	$5.4M
Free Cash Flow	-$134.1M
Total Assets	$610.2M
Total Liabilities	$290.7M
Equity	$319.6M

About Nuvation Bio Inc

Nuvation Bio Inc is a biopharmaceutical company tackling unmet needs in oncology by developing differentiated and novel therapeutic candidates. Its product candidate, taletrectinib, is an oral, potent, central nervous system-active, selective, next-generation c-ros oncogene 1 (ROS1) inhibitor designed for the treatment of patients with ROS1+ non-small cell lung cancer (NSCLC). In addition, its clinical-stage pipeline includes oncology product candidates such as Safusidenib, NUV-1511, and NUV-868 in different stages of development. The Company generates revenue from out-licensing collaborative agreements, including product revenue, upfront license fees, royalty revenue, and research and development services revenue. The Company generates the majority of its revenue from Japan.

Nuvation Bio Inc is a publicly traded company under the ticker symbol NUVB on the NEW YORK STOCK EXCHANGE, INC., operating in the Pharmaceuticals industry. Quotes and metrics shown here are sourced from public market data and refreshed regularly.